Anzeige
Mehr »
Montag, 11.08.2025 - Börsentäglich über 12.000 News
Desert Gold: Zahlen untermauern das Potential
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ3E | ISIN: US18507C1036 | Ticker-Symbol:
NASDAQ
08.08.25 | 22:00
10,820 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARPOINT NEURO INC Chart 1 Jahr
5-Tage-Chart
CLEARPOINT NEURO INC 5-Tage-Chart

Aktuelle News zur CLEARPOINT NEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.08.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio285SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to...
► Artikel lesen
23.07.ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025199SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation...
► Artikel lesen
17.06.ClearPoint Neuro, Inc. - 8-K, Current Report1
16.06.ClearPoint Neuro May 2025 presentation: Enters 'Fast Forward' phase after Q1 revenue beat5
19.05.ClearPoint Neuro, Inc. - 8-K, Current Report3
14.05.ClearPoint Neuro targets 15-20 new site activations in 2025 while advancing cell and gene therapy initiatives6
13.05.ClearPoint Neuro Reports Q1 Earnings: Revenue Beat, EPS Miss, Company Affirms FY25 Guidance3
CLEARPOINT NEURO Aktie jetzt für 0€ handeln
13.05.ClearPoint Neuro, Inc. - 10-Q, Quarterly Report3
13.05.ClearPoint Neuro, Inc.: ClearPoint Neuro Reports First Quarter 2025 Results361Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company")...
► Artikel lesen
13.05.ClearPoint Neuro secures $110M investment2
12.05.ClearPoint Neuro, Inc. Q1 2025 Earnings Preview1
12.05.ClearPoint Neuro sichert sich Finanzierung von bis zu 105 Millionen US-Dollar7
12.05.ClearPoint Neuro secures up to $105 million financing2
12.05.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing384SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation...
► Artikel lesen
12.05.ClearPoint Neuro, Inc. - 8-K, Current Report3
28.04.ClearPoint Neuro, Inc.: ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI147SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
28.04.ClearPoint Neuro expands FDA application for MRI system1
28.04.Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance4
25.04.ClearPoint Neuro launches new navigation software2
25.04.ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025300SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1